Objective To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal
tumor necrosis factor α antibody, in combination with methotrexate (MTX) in patients with …

Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid
arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for …

Background Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The
multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis …

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Objective. Trials of rheumatoid arthritis (RA) treatments report the average response in
multiple outcome measures for treated patients. It is more clinically relevant to test whether …

Background Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate,
a standard treatment for this disease. There is evidence that antitumour necrosis factor α (…

Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there
is no widely used definition of remission that is stringent but achievable and could be …

The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …